Related Experiment Video

Updated: Sep 28, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?

Erwin H Fleischmann1, Roland E Schmieder

  • 1Department of Internal Medicine 4/IV, University of Erlangen-Nuremberg, Breslauer Strasse 201, 90475 Nuremberg, Germany. roland.schmieder@rzmail.uni-erlangen.de

Current Cardiology Reports
|October 16, 2002
PubMed

Insights

Left ventricular hypertrophy (LVH) is a significant cardiovascular risk. Angiotensin receptor blockers and ACE inhibitors effectively reverse LVH, improving cardiovascular outcomes, unlike beta-blockers.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Pharmacology

Background:

  • Left ventricular hypertrophy (LVH) is a critical risk factor for cardiovascular morbidity and mortality.
  • Arterial hypertension is a primary cause of LVH, with the renin-angiotensin-aldosterone system playing a key pathophysiological role.
  • Nonpharmacologic treatments can be effective for LVH in mild essential hypertension.

Purpose of the Study:

  • To evaluate the efficacy of different antihypertensive drug classes in reversing left ventricular hypertrophy.
  • To compare the effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) against beta-blockers in LVH regression.
  • To determine if LVH regression is associated with improved cardiovascular outcomes.

Main Methods:

  • Analysis of multiple meta-analyses involving several thousand patients.
  • Review of large-scale prospective trials, including the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
  • Comparison of treatment effects on LVH reversal across different antihypertensive drug categories.

Main Results:

  • Meta-analyses consistently show ACEIs and ARBs achieve significantly better LVH reversal than beta-blockers.
  • The LIFE study confirmed the superiority of ARBs over beta-blockers in a large prospective trial.
  • LVH regression was demonstrated to be associated with better cardiovascular outcomes for the first time.

Conclusions:

  • Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are superior to beta-blockers for reversing left ventricular hypertrophy.
  • Regression of left ventricular hypertrophy is linked to improved cardiovascular prognosis.
  • Pharmacological treatment targeting the renin-angiotensin-aldosterone system is crucial for managing LVH.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...